Premium
Serum adiponectin and methylation of adiponectin gene promoter in peripheral blood of the patients with Alzheimer’s disease and vascular dementia
Author(s) -
Kaiyrlykyzy Aiym,
Tsoy Andrey,
Umbayev Bauyrzhan,
Olzhayev Farkhad,
Alzhanova Dinara,
Zhussupova Alma,
Zhumalin Aibek,
Masoud AbdulRazak,
Askarova Sholpan
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.041761
Subject(s) - adiponectin , medicine , methylation , endocrinology , dementia , vascular dementia , dna methylation , disease , gene , biology , gene expression , obesity , insulin resistance , genetics
Background There is increasing body of evidence indicating that adiponectin (APN), a protein hormone produced mainly by white adipose tissue, may be an independent risk factor for all‐cause dementias and Alzheimer’s disease (AD). A number of studies demonstrated that concentration of APN was increased in plasma of patients with mild cognitive impairment (MCI) and AD compared to healthy individuals. In contrast, some studies did not find significant changes in plasma adiponectin in AD patients, or even demonstrated lower plasma level of APN in MCI and AD compared to controls. These controversial data indicate that more studies are needed to reveal an association between plasma adiponectin and dementia. In the present study we have evaluated APN level in blood and analyzed APN gene methylation in patients with AD and vascular dementia (VD). Method Blood samples were obtained from the patients with AD (n =26), VD (n=31) and cognitively normal individuals (n =44). We measured serum adiponectin level using ELISA kit; APN gene methylation in blood was analyzed using bisulfite modification of DNA protocol followed by methylation specific PCR. Result Analysis of serum adiponectin levels showed a 3‐fold increase in participants with AD (p<0.001) and VD (p<0.001) compared to the control group. 15 out of 57 (26.3%) of the samples in dementia group vs 1 out of 44 (2.3%) of the control samples had a methylated adiponectin gene promoter (p=0.001). Methylation of the adiponectin gene promoter in peripheral blood occurred with relatively same frequency in individuals with AD and VD, 23% and 29%, respectively (p=0.765). In AD patients serum adiponectin level was almost twice as high in samples in which methylation was observed (p=0.0294). Conclusion Our data demonstrated that in people suffering from AD and VD there was an increase in the levels of serum adiponectin and amplified methylation of adiponectin gene promoter in peripheral blood. These findings may serve as a basis for the development of prognostic biomarkers of AD and VD. Nevertheless, more data collection is necessary for further analysis and interpretation.